ABSTRACT
Hepatitis C virus (HCV) is a hepatotropic RNA virus with an extraordinary propensity to persist in the vast majority of infected individuals. During replication, because of the inherent infidelity of the viral RNA polymerase, each progeny RNA genome contains mutations that lead to a continuous diversification of the viral population. Consequently, HCV circulates in vivo as a quasispecies, which is a dynamic distribution of divergent but closely related genomes subjected to a continuous process of genetic variation, competition, and selection. This genomic heterogeneity confers a remarkable advantage to the viral population allowing for a rapid adaptation to a changing environment when the virus is subject to selective constraints exerted by the host, such as antiviral immunity, or external to the host, such as antiviral therapy. The large reservoir of variants provided by the quasispecies represents a great challenge for the control of HCV infection and has important biologic implications for viral persistence, host cell tropism, antiviral drug resistance, and development of an HCV vaccine. This review discusses the molecular mechanisms of HCV genetic variation and the biologic and clinical relevance of the quasispecies nature of HCV.
KEYWORDS
Hepatitis C virus - quasispecies - compartmentalism - immune escape - viral persistence
REFERENCES
1
Domingo E, Sabo D, Taniguchi T, Weissmann C.
Nucleotide sequence heterogeneity of an RNA phage population.
Cell.
1978;
13
(4)
735-744
2
Domingo E, Wain-Hobson S.
The 30th anniversary of quasispecies. Meeting on ‘Quasispecies: past, present and future’.
EMBO Rep.
2009;
10
(5)
444-448
3
Eigen M.
Selforganization of matter and the evolution of biological macromolecules.
Naturwissenschaften.
1971;
58
(10)
465-523
4 Eigen M, Schuster P. The Hypercycle. A Principle of Natural Self-Organization. Berlin: Springer-Verlag; 1979
5 Houghton M. Hepatitis C virus. In: Fields B N, Knipe D M, Howley P M, Chanock R H, eds. Fields Virology. 3rd ed. Philadelphia, PA: Lippincott-Raven; 1996: 1035-1058
6
Lindenbach B D, Rice C M.
Unravelling hepatitis C virus replication from genome to function.
Nature.
2005;
436
(7053)
933-938
7
Branch A D, Stump D D, Gutierrez J A, Eng F, Walewski J L.
The hepatitis C virus alternate reading frame (ARF) and its family of novel products: the alternate reading frame protein/F-protein, the double-frameshift protein, and others.
Semin Liver Dis.
2005;
25
(1)
105-117
8
Holland J, Spindler K, Horodyski F, Grabau E, Nichol S, VandePol S.
Rapid evolution of RNA genomes.
Science.
1982;
215
(4540)
1577-1585
9 Domingo E. Virus evolution. In: Knipe D M, Howley P F, eds. Fields Virology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007: 389-421
10
Duffy S, Shackelton L A, Holmes E C.
Rates of evolutionary change in viruses: patterns and determinants.
Nat Rev Genet.
2008;
9
(4)
267-276
11
Holland J J, Domingo E, de la Torre J C, Steinhauer D A.
Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis.
J Virol.
1990;
64
(8)
3960-3962
12
Crotty S, Cameron C E, Andino R.
RNA virus error catastrophe: direct molecular test by using ribavirin.
Proc Natl Acad Sci U S A.
2001;
98
(12)
6895-6900
13
Kalinina O, Norder H, Mukomolov S, Magnius L O.
A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg.
J Virol.
2002;
76
(8)
4034-4043
14
Yokoyama K, Takahashi M, Nishizawa T et al..
Identification and characterization of a natural inter-genotypic (2b/1b) recombinant hepatitis C virus in Japan.
Arch Virol.
2011;
156
(9)
1591-1601
15
Neumann A U, Lam N P, Dahari H et al..
Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.
Science.
1998;
282
(5386)
103-107
16
Martell M, Esteban J I, Quer J et al..
Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution.
J Virol.
1992;
66
(5)
3225-3229
17
de la Torre J C, Holland J J.
RNA virus quasispecies populations can suppress vastly superior mutant progeny.
J Virol.
1990;
64
(12)
6278-6281
18
Domingo E, Martin V, Perales C et al..
Viruses as quasispecies: biological implications.
Curr Top Microbiol Immunol.
2006;
299
51-82
19
Domingo E, Holland J J.
RNA virus mutations and fitness for survival.
Annu Rev Microbiol.
1997;
51
151-178
20
Ruiz-Jarabo C M, Arias A, Baranowski E, Escarmís C, Domingo E.
Memory in viral quasispecies.
J Virol.
2000;
74
(8)
3543-3547
21 Eigen M, Biebricher C K. Sequence space and quasispecies distribution. In: Domingo E, Ahlquist P, Holland J J, eds. RNA Genetics. Vol. 3. Boca Raton, FL: CRC Press; 1988: 211-245
22
Steinhauer D A, Holland J J.
Rapid evolution of RNA viruses.
Annu Rev Microbiol.
1987;
41
409-433
23
Ogata N, Alter H J, Miller R H, Purcell R H.
Nucleotide sequence and mutation rate of the H strain of hepatitis C virus.
Proc Natl Acad Sci U S A.
1991;
88
(8)
3392-3396
24
Okamoto H, Kojima M, Okada S et al..
Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability.
Virology.
1992;
190
(2)
894-899
25
Lu L, Nakano T, Orito E, Mizokami M, Robertson B H.
Evaluation of accumulation of hepatitis C virus mutations in a chronically infected chimpanzee: comparison of the core, E1, HVR1, and NS5b regions.
J Virol.
2001;
75
(6)
3004-3009
26
Farci P, Alter H J, Wong D et al..
A long-term study of hepatitis C virus replication in non-A, non-B hepatitis.
N Engl J Med.
1991;
325
(2)
98-104
27
Thimme R, Oldach D, Chang K M, Steiger C, Ray S C, Chisari F V.
Determinants of viral clearance and persistence during acute hepatitis C virus infection.
J Exp Med.
2001;
194
(10)
1395-1406
28
Rehermann B.
Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence.
J Clin Invest.
2009;
119
(7)
1745-1754
29
Walker C M.
Adaptive immunity to the hepatitis C virus.
Adv Virus Res.
2010;
78
43-86
30
Dahari H, Major M, Zhang X et al..
Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production.
Gastroenterology.
2005;
128
(4)
1056-1066
31
Su A I, Pezacki J P, Wodicka L et al..
Genomic analysis of the host response to hepatitis C virus infection.
Proc Natl Acad Sci U S A.
2002;
99
(24)
15669-15674
32
Gale Jr M, Foy E M.
Evasion of intracellular host defence by hepatitis C virus.
Nature.
2005;
436
(7053)
939-945
33
Thimme R, Bukh J, Spangenberg H C et al..
Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease.
Proc Natl Acad Sci U S A.
2002;
99
(24)
15661-15668
34
Bertoletti A, Ferrari C.
Kinetics of the immune response during HBV and HCV infection.
Hepatology.
2003;
38
(1)
4-13
35
Lohmann V, Körner F, Koch J, Herian U, Theilmann L, Bartenschlager R.
Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.
Science.
1999;
285
(5424)
110-113
36
Lohmann V, Körner F, Dobierzewska A, Bartenschlager R.
Mutations in hepatitis C virus RNAs conferring cell culture adaptation.
J Virol.
2001;
75
(3)
1437-1449
37
Blight K J, Kolykhalov A A, Rice C M.
Efficient initiation of HCV RNA replication in cell culture.
Science.
2000;
290
(5498)
1972-1974
38
Smith D B, Mellor J, Jarvis L M The International HCV Collaborative Study Group et al.
Variation of the hepatitis C virus 5′ non-coding region: implications for secondary structure, virus detection and typing.
J Gen Virol.
1995;
76
(Pt 7)
1749-1761
39
Bukh J, Miller R H, Purcell R H.
Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes.
Semin Liver Dis.
1995;
15
(1)
41-63
40
Bukh J, Pietschmann T, Lohmann V et al..
Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees.
Proc Natl Acad Sci U S A.
2002;
99
(22)
14416-14421
41
Ray S C, Mao Q, Lanford R E et al..
Hypervariable region 1 sequence stability during hepatitis C virus replication in chimpanzees.
J Virol.
2000;
74
(7)
3058-3066
42
Prince A M, Pawlotsky J M, Soulier A et al..
Hepatitis C virus replication kinetics in chimpanzees with self-limited and chronic infections.
J Viral Hepat.
2004;
11
(3)
236-242
43
Bassett S E, Thomas D L, Brasky K M, Lanford R E.
Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees.
J Virol.
1999;
73
(2)
1118-1126
44
Bukh J.
A critical role for the chimpanzee model in the study of hepatitis C.
Hepatology.
2004;
39
(6)
1469-1475
45
Gómez J, Martell M, Quer J, Cabot B, Esteban J I.
Hepatitis C viral quasispecies.
J Viral Hepat.
1999;
6
(1)
3-16
46
Forns X, Bukh J, Purcell R H, Emerson S U.
How Escherichia coli can bias the results of molecular cloning: preferential selection of defective genomes of hepatitis C virus during the cloning procedure.
Proc Natl Acad Sci U S A.
1997;
94
(25)
13909-13914
47
Fishman S L, Branch A D.
The quasispecies nature and biological implications of the hepatitis C virus.
Infect Genet Evol.
2009;
9
(6)
1158-1167
48
Verbinnen T, Van Marck H, Vandenbroucke I et al..
Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing.
J Virol.
2010;
84
(21)
11124-11133
49
Hiraga N, Imamura M, Abe H et al..
Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo.
Hepatology.
2011;
Epub ahead of print
50
Wang G P, Sherrill-Mix S A, Chang K M, Quince C, Bushman F D.
Hepatitis C virus transmission bottlenecks analyzed by deep sequencing.
J Virol.
2010;
84
(12)
6218-6228
51
Bull R A, Luciani F, McElroy K et al..
Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection.
PLoS Pathog.
2011;
7
(9)
e1002243
52
Zinkernagel R M.
On natural and artificial vaccinations.
Annu Rev Immunol.
2003;
21
515-546
53
Farci P, Alter H J, Wong D C et al..
Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization.
Proc Natl Acad Sci U S A.
1994;
91
(16)
7792-7796
54
Shimizu Y K, Hijikata M, Iwamoto A et al..
Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses.
J Virol.
1994;
68
(3)
1494-1500
55
Farci P, Shimoda A, Wong D et al..
Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein.
Proc Natl Acad Sci U S A.
1996;
93
(26)
15394-15399
56
Shimizu Y K, Igarashi H, Kiyohara T et al..
A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures.
Virology.
1996;
223
(2)
409-412
57
Weiner A J, Geysen H M, Christopherson C et al..
Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections.
Proc Natl Acad Sci U S A.
1992;
89
(8)
3468-3472
58
Zeisel M B, Fafi-Kremer S, Fofana I et al..
Neutralizing antibodies in hepatitis C virus infection.
World J Gastroenterol.
2007;
13
(36)
4824-4830
59
Zibert A, Meisel H, Kraas W et al..
Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus.
Hepatology.
1997;
25
(5)
1245-1249
60
Kumar U, Monjardino J, Thomas H C.
Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient.
Gastroenterology.
1994;
106
(4)
1072-1075
61
Booth J C, Kumar U, Webster D, Monjardino J, Thomas H C.
Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients.
Hepatology.
1998;
27
(1)
223-227
62
Prince A M, Brotman B, Lee D H et al..
Significance of the anti-E2 response in self-limited and chronic hepatitis C virus infections in chimpanzees and in humans.
J Infect Dis.
1999;
180
(4)
987-991
63
Major M E, Dahari H, Mihalik K et al..
Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees.
Hepatology.
2004;
39
(6)
1709-1720
64
Bartosch B, Dubuisson J, Cosset F L.
Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes.
J Exp Med.
2003;
197
(5)
633-642
65
Hsu M, Zhang J, Flint M et al..
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles.
Proc Natl Acad Sci U S A.
2003;
100
(12)
7271-7276
66
Baumert T F, Ito S, Wong D T, Liang T J.
Hepatitis C virus structural proteins assemble into viruslike particles in insect cells.
J Virol.
1998;
72
(5)
3827-3836
67
Wakita T, Pietschmann T, Kato T et al..
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome.
Nat Med.
2005;
11
(7)
791-796
68
Lindenbach B D, Evans M J, Syder A J et al..
Complete replication of hepatitis C virus in cell culture.
Science.
2005;
309
(5734)
623-626
69
Bartosch B, Bukh J, Meunier J C et al..
In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes.
Proc Natl Acad Sci U S A.
2003;
100
(24)
14199-14204
70
Meunier J C, Engle R E, Faulk K et al..
Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1.
Proc Natl Acad Sci U S A.
2005;
102
(12)
4560-4565
71
Logvinoff C, Major M E, Oldach D et al..
Neutralizing antibody response during acute and chronic hepatitis C virus infection.
Proc Natl Acad Sci U S A.
2004;
101
(27)
10149-10154
72
Meunier J C, Bukh J, Diaz G et al..
Neutralizing antibodies to HCV in perinatally infected children followed prospectively.
J Infect Dis.
2011;
204
(11)
1741-1745
73
Pestka J M, Zeisel M B, Bläser E et al..
Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C.
Proc Natl Acad Sci U S A.
2007;
104
(14)
6025-6030
74
von Hahn T, Yoon J C, Alter H et al..
Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo.
Gastroenterology.
2007;
132
(2)
667-678
75
Dowd K A, Netski D M, Wang X H, Cox A L, Ray S C.
Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus.
Gastroenterology.
2009;
136
(7)
2377-2386
76
Lavillette D, Morice Y, Germanidis G et al..
Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection.
J Virol.
2005;
79
(10)
6023-6034
77
Bukh J, Thimme R, Meunier J C et al..
Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain.
J Virol.
2008;
82
(16)
8183-8195
78
Penin F, Combet C, Germanidis G, Frainais P O, Deléage G, Pawlotsky J M.
Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment.
J Virol.
2001;
75
(12)
5703-5710
79
Vieyres G, Dubuisson J, Patel A H.
Characterization of antibody-mediated neutralization directed against the hypervariable region 1 of hepatitis C virus E2 glycoprotein.
J Gen Virol.
2011;
92
(Pt 3)
494-506
80
Prentoe J, Jensen T B, Meuleman P et al..
Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization.
J Virol.
2011;
85
(5)
2224-2234
81
Forns X, Thimme R, Govindarajan S et al..
Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees.
Proc Natl Acad Sci U S A.
2000;
97
(24)
13318-13323
82
Bankwitz D, Steinmann E, Bitzegeio J et al..
Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes.
J Virol.
2010;
84
(11)
5751-5763
83
Zolla-Pazner S, Cardozo T.
Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design.
Nat Rev Immunol.
2010;
10
(7)
527-535
84
Ray S C, Wang Y M, Laeyendecker O, Ticehurst J R, Villano S A, Thomas D L.
Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy.
J Virol.
1999;
73
(4)
2938-2946
85
Keck Z Y, Op De Beeck A, Hadlock K G et al..
Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions.
J Virol.
2004;
78
(17)
9224-9232
86
Keck Z Y, Li S H, Xia J et al..
Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.
J Virol.
2009;
83
(12)
6149-6160
87
Diepolder H M, Zachoval R, Hoffmann R M et al..
Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection.
Lancet.
1995;
346
(8981)
1006-1007
88
Gerlach J T, Diepolder H M, Jung M C et al..
Recurrence of hepatitis C virus after loss of virus-specific CD4( + ) T-cell response in acute hepatitis C.
Gastroenterology.
1999;
117
(4)
933-941
89
Cooper S, Erickson A L, Adams E J et al..
Analysis of a successful immune response against hepatitis C virus.
Immunity.
1999;
10
(4)
439-449
90
Lechner F, Wong D K, Dunbar P R et al..
Analysis of successful immune responses in persons infected with hepatitis C virus.
J Exp Med.
2000;
191
(9)
1499-1512
91
Grakoui A, Shoukry N H, Woollard D J et al..
HCV persistence and immune evasion in the absence of memory T cell help.
Science.
2003;
302
(5645)
659-662
92
Shoukry N H, Grakoui A, Houghton M et al..
Memory CD8 + T cells are required for protection from persistent hepatitis C virus infection.
J Exp Med.
2003;
197
(12)
1645-1655
93
Gottwein J M, Scheel T K, Callendret B et al..
Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies.
J Virol.
2010;
84
(10)
5277-5293
94
Klenerman P, Thimme R.
T cell responses in hepatitis C: the good, the bad and the unconventional.
Gut.
2011;
Epub ahead of print
95
Bengsch B, Seigel B, Ruhl M et al..
Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8 + T cells is linked to antigen recognition and T cell differentiation.
PLoS Pathog.
2010;
6
(6)
e1000947
96
Neumann-Haefelin C, Thimme R.
Success and failure of virus-specific T cell responses in hepatitis C virus infection.
Dig Dis.
2011;
29
(4)
416-422
97
Weiner A, Erickson A L, Kansopon J et al..
Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant.
Proc Natl Acad Sci U S A.
1995;
92
(7)
2755-2759
98
Erickson A L, Kimura Y, Igarashi S et al..
The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes.
Immunity.
2001;
15
(6)
883-895
99
Chang K M, Rehermann B, McHutchison J G et al..
Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus.
J Clin Invest.
1997;
100
(9)
2376-2385
100
Timm J, Lauer G M, Kavanagh D G et al..
CD8 epitope escape and reversion in acute HCV infection.
J Exp Med.
2004;
200
(12)
1593-1604
101
Bowen D G, Walker C M.
Mutational escape from CD8 + T cell immunity: HCV evolution, from chimpanzees to man.
J Exp Med.
2005;
201
(11)
1709-1714
102
Cox A L, Mosbruger T, Mao Q et al..
Cellular immune selection with hepatitis C virus persistence in humans.
J Exp Med.
2005;
201
(11)
1741-1752
103
Ray S C, Fanning L, Wang X H et al..
Divergent and convergent evolution after a common-source outbreak of hepatitis C virus.
J Exp Med.
2005;
201
(11)
1753-1759
104
Tsai S L, Chen Y M, Chen M H et al..
Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity.
Gastroenterology.
1998;
115
(4)
954-965
105
Guglietta S, Garbuglia A R, Salichos L et al..
Impact of viral selected mutations on T cell mediated immunity in chronically evolving and self limiting acute HCV infection.
Virology.
2009;
386
(2)
398-406
106
Tester I, Smyk-Pearson S, Wang P et al..
Immune evasion versus recovery after acute hepatitis C virus infection from a shared source.
J Exp Med.
2005;
201
(11)
1725-1731
107
Fernandez J, Taylor D, Morhardt D R et al..
Long-term persistence of infection in chimpanzees inoculated with an infectious hepatitis C virus clone is associated with a decrease in the viral amino acid substitution rate and low levels of heterogeneity.
J Virol.
2004;
78
(18)
9782-9789
108
Kuntzen T, Timm J, Berical A et al..
Viral sequence evolution in acute hepatitis C virus infection.
J Virol.
2007;
81
(21)
11658-11668
109
Ruhl M, Knuschke T, Schewior K East German HCV Study Group et al.
CD8 + T-cell response promotes evolution of hepatitis C virus nonstructural proteins.
Gastroenterology.
2011;
140
(7)
2064-2073
110
Neumann-Haefelin C, McKiernan S, Ward S et al..
Dominant influence of an HLA-B27 restricted CD8 + T cell response in mediating HCV clearance and evolution.
Hepatology.
2006;
43
(3)
563-572
111
Kim A Y, Kuntzen T, Timm J et al..
Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes.
Gastroenterology.
2011;
140
(2)
686-696, e1
112
Cox A L, Mosbruger T, Lauer G M, Pardoll D, Thomas D L, Ray S C.
Comprehensive analyses of CD8 + T cell responses during longitudinal study of acute human hepatitis C.
Hepatology.
2005;
42
(1)
104-112
113
Neumann-Haefelin C, Timm J, Spangenberg H C et al..
Virological and immunological determinants of intrahepatic virus-specific CD8 + T-cell failure in chronic hepatitis C virus infection.
Hepatology.
2008;
47
(6)
1824-1836
114
Komatsu H, Lauer G, Pybus O G et al..
Do antiviral CD8 + T cells select hepatitis C virus escape mutants? Analysis in diverse epitopes targeted by human intrahepatic CD8 + T lymphocytes.
J Viral Hepat.
2006;
13
(2)
121-130
115
Uebelhoer L, Han J H, Callendret B et al..
Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness.
PLoS Pathog.
2008;
4
(9)
e1000143
116
Liu L, Fisher B E, Dowd K A, Astemborski J, Cox A L, Ray S C.
Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection.
J Virol.
2010;
84
(10)
5067-5077
117
Wang H, Eckels D D.
Mutations in immunodominant T cell epitopes derived from the nonstructural 3 protein of hepatitis C virus have the potential for generating escape variants that may have important consequences for T cell recognition.
J Immunol.
1999;
162
(7)
4177-4183
118
Fleming V M, Harcourt G, Barnes E, Klenerman P.
Virological footprint of CD4 + T-cell responses during chronic hepatitis C virus infection.
J Gen Virol.
2010;
91
(Pt 6)
1396-1406
119
Fuller M J, Shoukry N H, Gushima T et al..
Selection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection.
Hepatology.
2010;
51
(2)
378-387
120
Farci P, Quinti I, Farci S et al..
Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively.
Proc Natl Acad Sci U S A.
2006;
103
(22)
8475-8480
121
Farci P, Shimoda A, Coiana A et al..
The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies.
Science.
2000;
288
(5464)
339-344
122
Laskus T, Wilkinson J, Gallegos-Orozco J F et al..
Analysis of hepatitis C virus quasispecies transmission and evolution in patients infected through blood transfusion.
Gastroenterology.
2004;
127
(3)
764-776
123
Farci P, Strazzera R, Alter H J et al..
Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome.
Proc Natl Acad Sci U S A.
2002;
99
(5)
3081-3086
124
Manzin A, Solforosi L, Debiaggi M et al..
Dominant role of host selective pressure in driving hepatitis C virus evolution in perinatal infection.
J Virol.
2000;
74
(9)
4327-4334
125
Urbani S, Amadei B, Cariani E et al..
The impairment of CD8 responses limits the selection of escape mutations in acute hepatitis C virus infection.
J Immunol.
2005;
175
(11)
7519-7529
126
Alter H J, Seeff L B.
Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome.
Semin Liver Dis.
2000;
20
(1)
17-35
127
Yeo A E, Ghany M, Conry-Cantilena C et al..
Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers.
J Viral Hepat.
2001;
8
(4)
256-263
128
Honda M, Kaneko S, Sakai A, Unoura M, Murakami S, Kobayashi K.
Degree of diversity of hepatitis C virus quasispecies and progression of liver disease.
Hepatology.
1994;
20
(5)
1144-1151
129
Koizumi K, Enomoto N, Kurosaki M et al..
Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment.
Hepatology.
1995;
22
(1)
30-35
130
Hayashi J, Kishihara Y, Yamaji K et al..
Hepatitis C viral quasispecies and liver damage in patients with chronic hepatitis C virus infection.
Hepatology.
1997;
25
(3)
697-701
131
Yuki N, Hayashi N, Moribe T et al..
Relation of disease activity during chronic hepatitis C infection to complexity of hypervariable region 1 quasispecies.
Hepatology.
1997;
25
(2)
439-444
132
Naito M, Hayashi N, Moribe T et al..
Hepatitis C viral quasispecies in hepatitis C virus carriers with normal liver enzymes and patients with type C chronic liver disease.
Hepatology.
1995;
22
(2)
407-412
133
López-Labrador F X, Ampurdanès S, Giménez-Barcons M et al..
Relationship of the genomic complexity of hepatitis C virus with liver disease severity and response to interferon in patients with chronic HCV genotype 1b infection [correction of interferon].
Hepatology.
1999;
29
(3)
897-903
134
Leone F, Zylberberg H, Squadrito G et al..
Hepatitis C virus (HCV) hypervariable region 1 complexity does not correlate with severity of liver disease, HCV type, viral load or duration of infection.
J Hepatol.
1998;
29
(5)
689-694
135
Rothman A L, Morishima C, Bonkovsky H L HALT-C Trial Group et al.
Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C.
Hepatology.
2005;
41
(3)
617-625
136
Sullivan D G, Bruden D, Deubner H et al..
Hepatitis C virus dynamics during natural infection are associated with long-term histological outcome of chronic hepatitis C disease.
J Infect Dis.
2007;
196
(2)
239-248
137
Izopet J, Rostaing L, Sandres K et al..
Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients.
J Infect Dis.
2000;
181
(3)
852-858
138
Qin H, Shire N J, Keenan E D Multicenter Hemophilia Cohort Study Group et al.
HCV quasispecies evolution: association with progression to end-stage liver disease in hemophiliacs infected with HCV or HCV/HIV.
Blood.
2005;
105
(2)
533-541
139
Tagariello G, Gerotto M, Pontisso P et al..
Hepatitis C virus quasispecies in the natural course of HCV-related disease in patients with haemophilia.
Haemophilia.
2004;
10
(1)
81-86
140
Wang X H, Netski D M, Astemborski J et al..
Progression of fibrosis during chronic hepatitis C is associated with rapid virus evolution.
J Virol.
2007;
81
(12)
6513-6522
141
Ramírez S, Pérez-Del-Pulgar S, Forns X.
Virology and pathogenesis of hepatitis C virus recurrence.
Liver Transpl.
2008;
14
(Suppl 2)
S27-S35
142
Feliu A, Gay E, García-Retortillo M, Saiz J C, Forns X.
Evolution of hepatitis C virus quasispecies immediately following liver transplantation.
Liver Transpl.
2004;
10
(9)
1131-1139
143
Gretch D R, Polyak S J, Wilson J J, Carithers Jr R L, Perkins J D, Corey L.
Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients.
J Virol.
1996;
70
(11)
7622-7631
144
Sullivan D G, Wilson J J, Carithers Jr R L, Perkins J D, Gretch D R.
Multigene tracking of hepatitis C virus quasispecies after liver transplantation: correlation of genetic diversification in the envelope region with asymptomatic or mild disease patterns.
J Virol.
1998;
72
(12)
10036-10043
145
Sánchez-Fueyo A, Giménez-Barcons M, Puig-Basagoiti F et al..
Influence of the dynamics of the hypervariable region 1 of hepatitis C virus (HCV) on the histological severity of HCV recurrence after liver transplantation.
J Med Virol.
2001;
65
(2)
266-275
146
Lyra A C, Fan X, Lang D M et al..
Evolution of hepatitis C viral quasispecies after liver transplantation.
Gastroenterology.
2002;
123
(5)
1485-1493
147
Arenas J I, Gallegos-Orozco J F, Laskus T et al..
Hepatitis C virus quasi-species dynamics predict progression of fibrosis after liver transplantation.
J Infect Dis.
2004;
189
(11)
2037-2046
148
Li H, Sullivan D G, Feuerborn N et al..
Genetic diversity of hepatitis C virus predicts recurrent disease after liver transplantation.
Virology.
2010;
402
(2)
248-255
149
Lerat H, Berby F, Trabaud M A et al..
Specific detection of hepatitis C virus minus strand RNA in hematopoietic cells.
J Clin Invest.
1996;
97
(3)
845-851
150
Radkowski M, Wang L F, Vargas H E, Rakela J, Laskus T.
Detection of hepatitis C virus replication in peripheral blood mononuclear cells after orthotopic liver transplantation.
Transplantation.
1998;
66
(5)
664-666
151
Laskus T, Radkowski M, Piasek A et al..
Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes.
J Infect Dis.
2000;
181
(2)
442-448
152
Radkowski M, Wilkinson J, Nowicki M et al..
Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication.
J Virol.
2002;
76
(2)
600-608
153
Laskus T, Radkowski M, Wilkinson J, Vargas H, Rakela J.
The origin of hepatitis C virus reinfecting transplanted livers: serum-derived versus peripheral blood mononuclear cell-derived virus.
J Infect Dis.
2002;
185
(4)
417-421
154
Ducoulombier D, Roque-Afonso A M, Di Liberto G et al..
Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes.
Hepatology.
2004;
39
(3)
817-825
155
Roque-Afonso A M, Ducoulombier D, Di Liberto G et al..
Compartmentalization of hepatitis C virus genotypes between plasma and peripheral blood mononuclear cells.
J Virol.
2005;
79
(10)
6349-6357
156
Bagaglio S, Cinque P, Racca S et al..
Hepatitis C virus populations in the plasma, peripheral blood mononuclear cells and cerebrospinal fluid of HIV/hepatitis C virus-co-infected patients.
AIDS.
2005;
19
(Suppl 3)
S151-S165
157
Pal S, Sullivan D G, Kim S et al..
Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: implications of HCV lymphotropism.
Gastroenterology.
2006;
130
(4)
1107-1116
158
Blackard J T, Hiasa Y, Smeaton L et al..
Compartmentalization of hepatitis C virus (HCV) during HCV/HIV coinfection.
J Infect Dis.
2007;
195
(12)
1765-1773
159
McGuinness P H, Bishop G A, McCaughan G W, Trowbridge R, Gowans E J.
False detection of negative-strand hepatitis C virus RNA.
Lancet.
1994;
343
(8896)
551-552
160
Lanford R E, Chavez D, Chisari F V, Sureau C.
Lack of detection of negative-strand hepatitis C virus RNA in peripheral blood mononuclear cells and other extrahepatic tissues by the highly strand-specific rTth reverse transcriptase PCR.
J Virol.
1995;
69
(12)
8079-8083
161
Laskus T, Radkowski M, Wang L F, Cianciara J, Vargas H, Rakela J.
Hepatitis C virus negative strand RNA is not detected in peripheral blood mononuclear cells and viral sequences are identical to those in serum: a case against extrahepatic replication.
J Gen Virol.
1997;
78
(Pt 11)
2747-2750
162
Quadri R, Rubbia-Brandt L, Abid K, Negro F.
Detection of the negative-strand hepatitis C virus RNA in tissues: implications for pathogenesis.
Antiviral Res.
2001;
52
(2)
161-171
163
Madejón A, Manzano M L, Arocena C, Castillo I, Carreño V.
Effects of delayed freezing of liver biopsies on the detection of hepatitis C virus RNA strands.
J Hepatol.
2000;
32
(6)
1019-1025
164
Natarajan V, Kottilil S, Hazen A et al..
HCV in peripheral blood mononuclear cells are predominantly carried on the surface of cells in HIV/HCV co-infected individuals.
J Med Virol.
2010;
82
(12)
2032-2037
165
Pham T N, King D, Macparland S A et al..
Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection.
Gastroenterology.
2008;
134
(3)
812-822
166
Fujii K, Hino K, Okazaki M, Okuda M, Kondoh S, Okita K.
Differences in hypervariable region 1 quasispecies of hepatitis C virus between human serum and peripheral blood mononuclear cells.
Biochem Biophys Res Commun.
1996;
225
(3)
771-776
167
Cabot B, Esteban J I, Martell M et al..
Structure of replicating hepatitis C virus (HCV) quasispecies in the liver may not be reflected by analysis of circulating HCV virions.
J Virol.
1997;
71
(2)
1732-1734
168
Shimizu Y K, Igarashi H, Kanematu T et al..
Sequence analysis of the hepatitis C virus genome recovered from serum, liver, and peripheral blood mononuclear cells of infected chimpanzees.
J Virol.
1997;
71
(8)
5769-5773
169
Maggi F, Fornai C, Vatteroni M L et al..
Differences in hepatitis C virus quasispecies composition between liver, peripheral blood mononuclear cells and plasma.
J Gen Virol.
1997;
78
(Pt 7)
1521-1525
170
Navas S, Martín J, Quiroga J A, Castillo I, Carreño V.
Genetic diversity and tissue compartmentalization of the hepatitis C virus genome in blood mononuclear cells, liver, and serum from chronic hepatitis C patients.
J Virol.
1998;
72
(2)
1640-1646
171
Maggi F, Fornai C, Morrica A et al..
Divergent evolution of hepatitis C virus in liver and peripheral blood mononuclear cells of infected patients.
J Med Virol.
1999;
57
(1)
57-63
172
Okuda M, Hino K, Korenaga M, Yamaguchi Y, Katoh Y, Okita K.
Differences in hypervariable region 1 quasispecies of hepatitis C virus in human serum, peripheral blood mononuclear cells, and liver.
Hepatology.
1999;
29
(1)
217-222
173
Fishman S L, Murray J M, Eng F J, Walewski J L, Morgello S, Branch A D.
Molecular and bioinformatic evidence of hepatitis C virus evolution in brain.
J Infect Dis.
2008;
197
(4)
597-607
174
Waddle D M.
Matrix correlation tests support a single origin for modern humans.
Nature.
1994;
368
(6470)
452-454
175
Laskus T, Radkowski M, Bednarska A et al..
Detection and analysis of hepatitis C virus sequences in cerebrospinal fluid.
J Virol.
2002;
76
(19)
10064-10068
176
Forton D M, Karayiannis P, Mahmud N, Taylor-Robinson S D, Thomas H C.
Identification of unique hepatitis C virus quasispecies in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, and serum variants.
J Virol.
2004;
78
(10)
5170-5183
177
Lerat H, Shimizu Y K, Lemon S M.
Cell type-specific enhancement of hepatitis C virus internal ribosome entry site-directed translation due to 5′ nontranslated region substitutions selected during passage of virus in lymphoblastoid cells.
J Virol.
2000;
74
(15)
7024-7031
178
Laporte J, Malet I, Andrieu T et al..
Comparative analysis of translation efficiencies of hepatitis C virus 5′ untranslated regions among intraindividual quasispecies present in chronic infection: opposite behaviors depending on cell type.
J Virol.
2000;
74
(22)
10827-10833
179
Laporte J, Bain C, Maurel P, Inchauspe G, Agut H, Cahour A.
Differential distribution and internal translation efficiency of hepatitis C virus quasispecies present in dendritic and liver cells.
Blood.
2003;
101
(1)
52-57
180
Di Liberto G, Roque-Afonso A M, Kara R et al..
Clinical and therapeutic implications of hepatitis C virus compartmentalization.
Gastroenterology.
2006;
131
(1)
76-84
181
Ramirez S, Perez-Del-Pulgar S, Carrion J A et al..
Hepatitis C virus compartmentalization and infection recurrence after liver transplantation.
Am J Transplant.
2009;
9
(7)
1591-1601
182
Kurosaki M, Enomoto N, Sakamoto N et al..
Detection and analysis of replicating hepatitis C virus RNA in hepatocellular carcinoma tissues.
J Hepatol.
1995;
22
(5)
527-535
183
De Mitri M S, Mele L, Chen C H et al..
Comparison of serum and liver hepatitis C virus quasispecies in HCV-related hepatocellular carcinoma.
J Hepatol.
1998;
29
(6)
887-892
184
De Mitri M S, Cassini R, Bagaglio S et al..
Evolution of hepatitis C virus non-structural 5A gene in the progression of liver disease to hepatocellular carcinoma.
Liver Int.
2007;
27
(8)
1126-1133
185
Sobesky R, Feray C, Rimlinger F et al..
Distinct hepatitis C virus core and F protein quasispecies in tumoral and nontumoral hepatocytes isolated via microdissection.
Hepatology.
2007;
46
(6)
1704-1712
186
Afdhal N H, McHutchison J G, Zeuzem S Pharmacogenetics and Hepatitis C Meeting Participants et al.
Hepatitis C pharmacogenetics: state of the art in 2010.
Hepatology.
2011;
53
(1)
336-345
187
Ge D, Fellay J, Thompson A J et al..
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.
Nature.
2009;
461
(7262)
399-401
188
Tanaka Y, Nishida N, Sugiyama M et al..
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.
Nat Genet.
2009;
41
(10)
1105-1109
189
Suppiah V, Moldovan M, Ahlenstiel G et al..
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.
Nat Genet.
2009;
41
(10)
1100-1104
190
Thomas D L, Thio C L, Martin M P et al..
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.
Nature.
2009;
461
(7265)
798-801
191
Wohnsland A, Hofmann W P, Sarrazin C.
Viral determinants of resistance to treatment in patients with hepatitis C.
Clin Microbiol Rev.
2007;
20
(1)
23-38
192
Okada S, Akahane Y, Suzuki H, Okamoto H, Mishiro S.
The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients.
Hepatology.
1992;
16
(3)
619-624
193
Kanazawa Y, Hayashi N, Mita E et al..
Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients.
Hepatology.
1994;
20
(5)
1121-1130
194
Moribe T, Hayashi N, Kanazawa Y et al..
Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to interferon therapy.
Gastroenterology.
1995;
108
(3)
789-795
195
Nagasaka A, Hige S, Tsunematsu I et al..
Changes in hepatitis C virus quasispecies and density populations in patients before and after interferon therapy.
J Med Virol.
1996;
50
(3)
214-220
196
Polyak S J, Faulkner G, Carithers Jr R L, Corey L, Gretch D R.
Assessment of hepatitis C virus quasispecies heterogeneity by gel shift analysis: correlation with response to interferon therapy.
J Infect Dis.
1997;
175
(5)
1101-1107
197
Le Guen B, Squadrito G, Nalpas B et al..
Hepatitis C virus genome complexity correlates with response to interferon therapy: a study in French patients with chronic hepatitis C.
Hepatology.
1997;
25
(5)
1250-1254
198
Pawlotsky J M, Pellerin M, Bouvier M et al..
Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C.
J Med Virol.
1998;
54
(4)
256-264
199
Hino K, Yamaguchi Y, Fujiwara D et al..
Hepatitis C virus quasispecies and response to interferon therapy in patients with chronic hepatitis C: a prospective study.
J Viral Hepat.
2000;
7
(1)
36-42
200
Chambers T J, Fan X, Droll D A et al..
Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection.
J Virol.
2005;
79
(5)
3071-3083
201
Morishima C, Polyak S J, Ray R Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group et al.
Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C.
J Infect Dis.
2006;
193
(7)
931-940
202
Torres-Puente M, Cuevas J M, Jiménez-Hernández N et al..
Genetic variability in hepatitis C virus and its role in antiviral treatment response.
J Viral Hepat.
2008;
15
(3)
188-199
203
Moreau I, Levis J, Crosbie O, Kenny-Walsh E, Fanning L J.
Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a.
Virol J.
2008;
5
78
204
Saludes V, Bracho M A, Valero O et al..
Baseline prediction of combination therapy outcome in hepatitis C virus 1b infected patients by discriminant analysis using viral and host factors.
PLoS ONE.
2010;
5
(11)
e14132
205
Nakazawa T, Kato N, Ohkoshi S, Shibuya A, Shimotohno K.
Characterization of the 5′ noncoding and structural region of the hepatitis C virus genome from patients with non-A, non-B hepatitis responding differently to interferon treatment.
J Hepatol.
1994;
20
(5)
623-629
206
López-Labrador F X, Ampurdanès S, Giménez-Barcons M et al..
Relationship of the genomic complexity of hepatitis C virus with liver disease severity and response to interferon in patients with chronic HCV genotype 1b infection [correction of interferon].
Hepatology.
1999;
29
(3)
897-903
207
Sandres K, Dubois M, Pasquier C et al..
Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy.
J Virol.
2000;
74
(2)
661-668
208
Fan X, Mao Q, Zhou D et al..
High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy.
Hepatology.
2009;
50
(6)
1765-1772
209
Polyak S J, McArdle S, Liu S L et al..
Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection.
J Virol.
1998;
72
(5)
4288-4296
210
Pawlotsky J M, Germanidis G, Frainais P O et al..
Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy.
J Virol.
1999;
73
(8)
6490-6499
211
Abbate I, Lo Iacono O, Di Stefano R et al..
HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin.
J Hepatol.
2004;
40
(5)
831-836
212
Sherman K E, Rouster S D, Stanford S AIDS Clinical Trials Group 5071 Study Team et al.
Hepatitis C virus (HCV) quasispecies complexity and selection in HCV/HIV-coinfected subjects treated with interferon-based regimens.
J Infect Dis.
2010;
201
(5)
712-719
213
Thelu M A, Baud M, Leroy V, Seigneurin J M, Zarski J P.
Dynamics of viral quasispecies during interferon therapy in non responder chronic hepatitis C patients.
J Clin Virol.
2001;
22
(1)
125-131
214
Enomoto N, Sakuma I, Asahina Y et al..
Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region.
J Clin Invest.
1995;
96
(1)
224-230
215
Enomoto N, Sakuma I, Asahina Y et al..
Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection.
N Engl J Med.
1996;
334
(2)
77-81
216
Sáiz J C, López-Labrador F X, Ampurdanés S et al..
The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus.
J Infect Dis.
1998;
177
(4)
839-847
217
Puig-Basagoiti F, Sáiz J C, Forns X et al..
Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C.
J Med Virol.
2001;
65
(1)
35-44
218
Hayashi K, Katano Y, Honda T et al..
Mutations in the interferon sensitivity-determining region of hepatitis C virus genotype 2a correlate with response to pegylated-interferon-alpha 2a monotherapy.
J Med Virol.
2009;
81
(3)
459-466
219
Khorsi H, Castelain S, Wyseur A et al..
Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients.
J Hepatol.
1997;
27
(1)
72-77
220
Squadrito G, Leone F, Sartori M et al..
Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa.
Gastroenterology.
1997;
113
(2)
567-572
221
Jardim A C, Yamasaki L H, de Queiróz A T et al..
Quasispecies of hepatitis C virus genotype 1 and treatment outcome with peginterferon and ribavirin.
Infect Genet Evol.
2009;
9
(4)
689-698
222
Halfon P, Locarnini S.
Hepatitis C virus resistance to protease inhibitors.
J Hepatol.
2011;
55
(1)
192-206
223
Wainberg M A, Zaharatos G J, Brenner B G.
Development of antiretroviral drug resistance.
N Engl J Med.
2011;
365
(7)
637-646
224
Sarrazin C, Kieffer T L, Bartels D et al..
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.
Gastroenterology.
2007;
132
(5)
1767-1777
225
Bartels D J, Zhou Y, Zhang E Z et al..
Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.
J Infect Dis.
2008;
198
(6)
800-807
226
Kuntzen T, Timm J, Berical A et al..
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients.
Hepatology.
2008;
48
(6)
1769-1778
227
Cubero M, Esteban J I, Otero T et al..
Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient.
Virology.
2008;
370
(2)
237-245
228
Kim A Y, Timm J, Nolan B E et al..
Temporal dynamics of a predominant protease inhibitor-resistance mutation in a treatment-naive, hepatitis C virus-infected individual.
J Infect Dis.
2009;
199
(5)
737-741
229
Nijhuis M, van Maarseveen N M, Boucher C A.
Antiviral resistance and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases.
Handb Exp Pharmacol.
2009;
189
(189)
299-320
230
Shimakami T, Welsch C, Yamane D et al..
Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus.
Gastroenterology.
2011;
140
(2)
667-675
Patrizia Farci
National Institutes of Health, 50 South Drive, MSC 8009
Building 50, Room 6529, Bethesda, MD 20892
eMail: pfarci@niaid.nih.gov